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responsibility of XAbstract YK-1101, with its structure as S-((E)-4-((7S,10S,Z)-4-ethylidene-7-isopropyl-2,5,8,12-
tetraoxo -9-oxa-16-thia-3,6,13,18-tetraazabicyclo[13.2.1]octadeca-1(17),15(18)-dien-10-yl)but-3-en-1-yl)
ethanethioate, is synthesized as a potential histone deacetylase inhibitor. Its quality and stability under
various stress conditions are not fully understood. In this study, a high performance liquid
chromatographic (HPLC) method was established and validated for the analysis of YK-1101 bulk
drug samples. The chromatographic separation was performed on a C18 column with acetonitrile and
water as mobile phase in a gradient elution. Based on the established method, the stability studies of
YK-1101 under various stress conditions were carried out. YK-1101 was shown to undergo
degradation under basic and acidic stress conditions, while it was stable under oxidative, photolytic
and thermal conditions. In addition, a time of ﬂight mass spectrometer (TOF/MS) was coupled to
HPLC for the characterization of major degradation products produced under basic and acidic stress
conditions. Their degradation pathways were also discussed.
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i’an Jiaotong University.1. Introduction
YK-1101 is a novel depsipeptide with its chemical structure
as S-((E)-4-((7S,10S,Z)-4-ethylidene- 7-isopropyl-2,5,8,12-tet-
raoxo-9-oxa-16-thia-3,6,13,18-tetraazabicyclo[13.2.1]octadeca-
1(17),15(18)-dien-10-yl)but-3-en-1-yl)ethanethioate (Fig. 1).
It was designed and synthesized as a histone deacetylase (HDAC)
inhibitor. HDACs are enzymes which catalyze the removal
of the acetyl moiety from acetyl-lysine within histones tolsevier B.V. All rights reserved.
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Fig. 1 Structure of YK-1101.
Stress studies and degradation products of YK-1101 169promote gene repression and silencing [1]. It was reported that
HDAC inhibitors could inhibit proliferation, induce differen-
tiation or apoptosis of tumor cells and activate gene transcrip-
tion [2–4]. HDAC inhibition has been shown to be a successful
strategy to treat certain forms of cancer. Two compounds,
vorinostat [5] and romidepsin [6], are already on the market,
while several others are in different stages of clinical trials,
such as apicidin [7], dolastatin 10 [8], ET-747 and aplidine [9].
Although its pharmacological activity has been demon-
strated, the quality and stability of YK-1101 are not fully
understood. There has been no study reported on the deter-
mination and stability of this new medical compound. Hence,
the aim of the study is to establish a rapid, speciﬁc and routine
analytical method for its quality control. The established
method was optimized and validated as per the guidelines of
International Conference on Harmonization (ICH) [10,11].
The forced degradation studies, which could help to establish
the degradation pathways and study the intrinsic stability
of the molecule, were also carried out in this study. A high
performance liquid chromatography with time of ﬂight mass
spectrometer (HPLC–TOF/MS) was established for the char-
acterization of degradation products. Their degradation path-
ways were also discussed.2. Experimental
2.1. Chemicals and reagents
Samples and reference standard of YK-1101 were supplied by
Yoko Pharma Co., Ltd. (Nanjing, China). HPLC-grade aceto-
nitrile was purchased from TIDEA Co., Ltd. (Fairﬁeld, USA).
Other analytical grade reagents were purchased from Nanjing
Chemical Co., Ltd. (Nanjing, China). Water for HPLC ana-
lysis was puriﬁed by a Milli-Q water system (Millipore, USA).
2.2. Sample preparation and stress studies
A degassed mixture of acetonitrile–water (20780, v/v) was used
as diluent during preparation of the standard and test
solutions. Stock solution of 1.0 mg/mL of YK-1101 sample
was prepared in the diluent for the determination of related
substances and stress studies. The stock solution was diluted
to 180 mg/mL for assay. The corresponding reference standard
solution of YK-1101 was also prepared in this diluent.
All the stress studies were carried out as per ICH require-
ment. Basic, acidic, oxidative, photolytic and thermal degra-
dation was performed, respectively, in 0.01 M NaOH, 1 M
HCl in 60 1C water bath, 30% hydrogen peroxide,illumination of 1.2 million lx and 80 1C water bath. Samples
were withdrawn at appropriate time, the pH was adjusted to
neutral and the samples were subjected to HPLC–TOF/MS
analysis. The stability of YK-1101 was observed and the
resolution between YK-1101 and its degradation products
was calculated to evaluate the potential impurities and the
speciﬁcity of the proposed method.
2.3. Apparatus and conditions
HPLC analysis was performed on a Shimadzu LC-2010 system
consisted of a quaternary pump, a vacuum degasser, an
autosampler and a column heater-cooler. An Inertsil ODS-
SP column (4.6 mm 250 mm, 5 mm) purchased from GL
Sciences Inc. (Japan) with a security guard was used for
separation. Acetonitrile (solvent A) and water (solvent B) were
used as mobile phase with the following gradient elution
mode: 20–30% A in 0–10 min; 30% A in 10–35 min;
30–40% A in 35–40 min; 40% A in 40–60 min and re-
equilibration duration was 5 min. The ﬂow rate was 1 mL/
min and the injection volume was 20 mL. The column
temperature was maintained at 30 1C. Detection wavelength
was set at 226 nm.
MS analysis was carried out using an Agilent 6224 TOF
LC–MS system. An electrospray ionization (ESI) was
employed and set in positive ion mode. The spray voltage
was set to 5.0 kV and the capillary temperature was main-
tained at 350 1C. Nitrogen was used as both the drying and
nebulizing gas. The scanning range was m/z 50–1000. Analy-
tical data were acquired using Agilent Masshunter work-
station software 4.0.
2.4. Validation of the method
2.4.1. Speciﬁcity
Speciﬁcity is the ability of the method to measure the analyte
response in the presence of its potential impurities and degra-
dation products. Degradation studies were conducted by
stressing under acidic, basic, oxidative, thermal and photolytic
conditions according to option 2 of Q1B in ICH guidelines.
2.4.2. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The LOD and LOQ for YK-1101 were estimated at a signal-
to-noise ratio of 3:1 and 10:1, respectively, by injecting a series
of diluted standard solutions with known concentrations.
2.4.3. Linearity
Linearity for YK-1101 was prepared by diluting the stock
reference standard solution to a series of required concentra-
tions at 60, 120, 180, 240 and 300 mg/mL. The calibration
curves were drawn by plotting the peak area of the target
analyte versus its corresponding concentration. The linear
range of YK-1101 was from 33.3% to 166.6% with respect to
sample concentration of 180 mg/mL.
2.4.4. Precision
Precision of the method was veriﬁed by repeatability and
intermediate precision studies. Repeatability studies were
performed by analysis of test solution in hexaplicate on 3
C. Zhou et al.170days. Intermediate precision of the method was checked by
different analysts on different days using different instruments.
2.4.5. Accuracy
The accuracy of the method was evaluated in triplicate by
adding appropriate amounts of the reference standard solu-
tion of the target compound into the test solution of YK-1101
at three different levels (i.e., 80%, 100% and 120%) with
respect to the concentration of test solution at 180 mg/mL, and
the mean recoveries were calculated.
2.4.6. Robustness
To evaluate the robustness of the established method, the
chromatographic conditions were deliberately altered and the
resolutions were calculated. Column temperatures of 25 1C
and 35 1C instead of 30 1C, detection wavelengths of 221 and
231 nm instead of 226 nm, and three different ODS columns
were employed and the resolutions were studied.Fig. 2 Typical HPLC chromatograms of: (A) YK-1101 test solution,
study under 1 M HCl in 60 1C water bath.
Table 1 Robustness testing for YK-1101.
Factor
Column temperature (1C)
25
30
35
Detection wavelength (nm)
221
226
231
Different columns
Inertsil ODS-SP (4.6 mm 250 mm, 5 mm)
Megres C18 (4.6 mm 250 mm, 5 mm)
Hedera ODS-2 (4.6 mm 250 mm, 5 mm)3. Results and discussion
3.1. Optimization of HPLC condition
In order to achieve satisfactory separation, chromatography
conditions, such as column types, mobile phase composition
and time program, were optimized. Preliminary experiments
were carried out by subjecting sample preparation to various
types and brands of commercial HPLC columns (Kromasil
KR60-5CN, BDS Hypersil Phenyl, Lichrospher C8, etc.), and
an Inertsil ODS-SP column (4.6 mm 250 mm, 5 mm) was
selected. Buffers such as triethylamine solution and phos-
phate buffer at different pH, and organic modiﬁers, including
methanol and acetonitrile, were tried. It turned out that
acetonitrile and water with gradient elution (mentioned in
Section 2.3) showed the best column efﬁciency and satisfactory
resolution. The optimized chromatogram is presented in
Fig. 2A.(B) basic stress study under 0.01 M NaOH, and (C) acidic stress
Resolution Tailing factor
2.0 1.17
2.1 1.15
2.1 1.14
2.1 1.15
2.1 1.15
2.1 1.16
2.1 1.15
2.0 1.15
1.9 1.00
Fig. 3 Typical TIC and MS of: (A) YK-1101 sample, (B) degradation product 1, and (C) degradation product 2.
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Fig. 4 Proposed degradation pathways of YK-1101 under stress
Stress studies and degradation products of YK-1101 1713.2. Results of method validation
The LOD and LOQ for YK-1101 were 0.026 and 0.077 mg/mL,
respectively. The linearity test for the assay of YK-1101 was
carried out by injecting a series of YK-1101 solutions with con-
centrations at 60, 120, 180, 240 and 300 mg/mL and the peak
areas were recorded. The values of slope, intercept and correla-
tion coefﬁcient were 42622, 150147 and 0.9999, respectively.
The RSD percentage for assay of YK-1101 during precision
study was within 0.5%, and the RSD percentage in the
intermediate precision study was within 1.0%, conﬁrming
the good precision of the established HPLC method.
The accuracy of the assay method was evaluated in triplicate
at three concentration levels. The percentage recoveries of
YK-1101 ranged from 99.2% to 102.2%.
The robustness results (Table 1) showed that the resolutions
between YK-1101 and its adjacent peaks were always greater
than 1.5, and the tailing factors were within 1.18, conﬁrming
the robustness of the method.conditions.3.3. Results of forced degradation studies
3.3.1. Thermal, photolytic and oxidative degradation
YK-1101 was found to be stable under thermal, photolytic
and oxidative conditions. No signiﬁcant degradation products
were observed.3.3.2. Basic degradation
YK-1101 was degraded under basic stress condition.
The typical chromatogram under 0.01 M NaOH is presented
in Fig. 2B. A major degradation product (degradation product
1) with its retention time at 18.2 min was detected. When the
strength of NaOH solution was increased to 0.1 M, YK-1101
degraded completely. Under the conditions of phosphate
buffer solution (pH 7.0–8.0), 0.001 M and 0.005 M NaOH,
no signiﬁcant degradation products were observed by the
established method.3.3.3. Acidic degradation
YK-1101 was stable when treated with 1 M HCl for 4 h at
room temperature. However, when the temperature of water
bath was increased to 60 1C, about 20% of YK-1101was
degraded (Fig. 2C). The major degradation product (degrada-
tion product 2) with its retention time at 28.2 min was detected
and further studied by LC–TOF/MS [12].3.4. Structure prediction of the major degradation products
The typical (þ)TIC of test solution is shown in Fig. 3.
YK-1101 with its retention time at 33.8 min and a related
compound with the retention time at 35.7 min showed the
same [MþH]þ ion at m/z 523.1. Therefore, the related
compound was an isomer of YK-1101.
C. Zhou et al.172As shown in Fig. 3B, the [MþH]þ ion for degradation
product 1 was at m/z 541.17845 (C23H32N4O7S2), which was
18u more than that of YK-1101. Therefore, it was the
hydrolysis product of YK-1101. Regarding the structure of
YK-1101, there are an ester and three amide bonds which
might be hydrolyzed. As amides are generally more stable
towards alkaline hydrolysis than esters [13–15], accordingly,
the ester group in the structure of YK-1101 is preferred to
undergo alkaline hydrolysis. As shown in Fig. 3C, the
[MþH]þ ion for degradation product 2 was at m/z
481.15493 (C21H28N4O5S2), which was 42u less than that of
YK-1101. It could be explained as the thioester being hydro-
lyzed under acidic condition and a sulfhydryl formed [16]. The
proposed degradation pathways for the two compounds are
presented in Fig. 4.4. Conclusion
In this work, a stability-indicating HPLC method was estab-
lished to investigate the effects of pH, temperature, light and
hydrogen peroxide on the stability of YK-1101. As the result,
YK-1101 was shown to undergo degradation under basic
and acidic stress conditions, and two degradation products
were proposed by the established HPLC–TOF/MS method.
The method was also validated with respect to speciﬁcity,
linearity, accuracy, precision and robustness, and found to be
suitable for checking the quality of bulk samples of YK-1101
at the time of batch release and also during its stability studies.
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